Recommendations on the Clinical Application and Future Potential of α-Particle Therapy. A Comprehensive Review of the Results from the SECURE Project
Authors:
- Valentina Di IorioValentina Di Iorio
- Anna SarnelliASAnna Sarnelli
- Stefano BoschiStefano Boschi
- Maddalena SansoviniMaddalena Sansovini
- Rosa Maria GenoveseRGRosa Maria Genovese
- Cipriana StefanescuCSCipriana Stefanescu
- Vlad GhizdovatVGVlad Ghizdovat
- Wael JalloulWJWael Jalloul
- Jennifer YoungJYJennifer Young
- Jane SosabowskiJSJane Sosabowski
- Petra KolencPetra Kolenc
- Rachel RobertsRRRachel Roberts
Preprint
- 13 August 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives The document comprehensively reviews the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 (Ra-223) therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in treatment of prostate cancer. The EU SECURE project was introduced as a major initiative to enhance the sustainability and safety of medical alpha-emitting radionuclides production in Europe. Methods: This literature review was conducted by a multidisciplinary team on selected radionuclides, including actinium-225, bismuth-213, astatine-211, lead-212, terbium-149, radium-22323 and thorium-227. These were selected based on their clinical significance, as identified in the EU PRISMAP project and subsequent literature searches. The review process involved searching major databases using specific keywords related to alpha-emitter therapy and was limited to articles in English. For each selected radionuclide, the physical characteristics, the radiochemistry, and the pre-clinical and clinical studies are explored. Results of the review show current and potential clinical applications of new alpha-emitting radionuclides, sharing insights from the SECURE consortium’s experiences and providing recommendations for future clinical trials to establish the therapeutic efficacy of these radionuclides. Conclusion: For each selected radionuclide, conclusion are reported in individual chapters. The results highlight the advantages of alpha particles in targeting cancer cells with minimal radiation to normal tissue, emphasising the need for high specificity and stability in delivery mechanisms, but also suggest that the full clinical potential of alpha particle therapy remains unexplored. Theranostic approach and dosimetric evaluations still represent relevant challenges.Keywords
All Related Versions
- Version 1, 2025-08-13, Preprints
- Published version: Pharmaceuticals, 18 (10), 1578.
This publication has 209 references indexed in Scilit:
- Sub‐10 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha TherapyChemistryOpen, 2020
- Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demandJournal of Labelled Compounds and Radiopharmaceuticals, 2019
- Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- AstatineJournal of Labelled Compounds and Radiopharmaceuticals, 2018
- Measurement of Terbium Isotopes Yield in Irradiation of 151Eu Targets by 3He NucleiAtomic Energy, 2017
- 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experienceEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximabEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Terbium-149 for nuclear medicine. The production of 149Tb via heavy ions induced nuclear reactionsCzechoslovak Journal of Physics, 2003